Related content

Phase I Trial of Fixed Dose Rate Infusion Gemcitabine with Gefitinib in Patients with Pancreatic Carcinoma

By Carneiro Benedito A.   Brand Randall E.   Fine Elita   Knop Richard H.   Khandekar Janardan D.   Uhlig William   Locker Gershon Y.  

Cancer Investigation, Vol. 25, Iss. 5, 2007-07 ,pp. : 366-371

Informa Healthcare

Access to resources Recommend Favorite

A Phase I––II dose escalation study of fixed-dose rate gemcitabine, oxaliplatin and capecitabine every two weeks in advanced cholangiocarcinomas

By Lassen Ulrik   Jensen Lars Henrik   Sorensen Morten   Rohrberg Kristoffer S.   Ujmajuridze Zaza   Jakobsen Anders  

Acta Oncologica, Vol. 50, Iss. 3, 2011-04 ,pp. : 448-454

Informa Healthcare

Access to resources Recommend Favorite

Epirubicin, cisplatin, oral UFT, and leucovorin combination chemotherapy in advanced and metastatic esophageal cancer

By Choi In   Seo Hee   Sung Hwa   Park Kyong   Kim Seok   Oh Sang   Seo Jae   Choi Chul   Kim Byung   Shin Sang   Kim Yeul   Kim Jun  

Medical Oncology, Vol. 24, Iss. 1, 2007-01 ,pp. : 33-37

Humana Press, Inc

Access to resources Recommend Favorite

The efficacy and relationship between peak concentration and toxicity profile of fixed-dose-rate gemcitabine plus carboplatin in patients with advanced non-small-cell lung cancer

By Wang Linrun   Wu Xiuhua   Huang Mingzhu   Cai Jie   Xu Nong   Liu Jian  

Cancer Chemotherapy and Pharmacology, Vol. 60, Iss. 2, 2007-07 ,pp. : 211-218

Springer Publishing Company

Access to resources Recommend Favorite

Use of cetuximab in combination with pulsed reduced dose-rate radiotherapy in a patient with recurrence of nasopharyngeal carcinoma in the neck

By          

Experimental and Therapeutic Medicine, Vol. 3, Iss. 5, 2012-01 ,pp. : 869-872

Spandidos Publications

Access to resources Recommend Favorite